Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies

Silvia Benvenuti, Andrea Sartore-Bianchi, Federica Di Nicolantonio, Carlo Zanon, Mauro Moroni, Silvio Veronese, Salvatore Siena, Alberto Bardelli

Research output: Contribution to journalArticle

677 Citations (Scopus)

Abstract

Monoclonal antibodies (mAbs) against the extracellular domain of the epidermal growth factor receptor (EGFR) have been introduced for the treatment of metastatic colorectal cancer (mCRC). We have reported recently that increased copy number of the EGFR can predict response to anti-EGFR mAbs and that patients might be selected for treatment based on EGFR copy number. Here, we show that mutations activating the RAS/RAF signaling pathway are also predictive and prognostic indicators in mCRC patients, being inversely correlated with response to anti-EGFR mAbs. In cellular models of CRCs, activation of the RAS signaling pathway by introduction of an activated K-RAS allele (Gly 12Val) impairs the therapeutic effect of anti-EGFR mAbs. In cancer cells carrying constitutively active RAS, the pharmacologic inhibition of the mitogen-activated protein kinase (MAPK) signaling cascade improves anti-EGFR treatment based on mAbs. These results have implications for the identification of patients who are likely to respond to anti-EGFR treatment. They also provide the rationale for combination therapies, targeted simultaneously to the EGFR and RAS/ RAF/MAPK signaling pathways in CRC patients.

Original languageEnglish
Pages (from-to)2643-2648
Number of pages6
JournalCancer Research
Volume67
Issue number6
DOIs
Publication statusPublished - Mar 15 2007

Fingerprint

Epidermal Growth Factor Receptor
Colorectal Neoplasms
Antibodies
Monoclonal Antibodies
Therapeutics
Mitogen-Activated Protein Kinases
Therapeutic Uses
Alleles
Mutation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. / Benvenuti, Silvia; Sartore-Bianchi, Andrea; Di Nicolantonio, Federica; Zanon, Carlo; Moroni, Mauro; Veronese, Silvio; Siena, Salvatore; Bardelli, Alberto.

In: Cancer Research, Vol. 67, No. 6, 15.03.2007, p. 2643-2648.

Research output: Contribution to journalArticle

Benvenuti, Silvia ; Sartore-Bianchi, Andrea ; Di Nicolantonio, Federica ; Zanon, Carlo ; Moroni, Mauro ; Veronese, Silvio ; Siena, Salvatore ; Bardelli, Alberto. / Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. In: Cancer Research. 2007 ; Vol. 67, No. 6. pp. 2643-2648.
@article{12f3848366714ae382f1ecd3c5e78bba,
title = "Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies",
abstract = "Monoclonal antibodies (mAbs) against the extracellular domain of the epidermal growth factor receptor (EGFR) have been introduced for the treatment of metastatic colorectal cancer (mCRC). We have reported recently that increased copy number of the EGFR can predict response to anti-EGFR mAbs and that patients might be selected for treatment based on EGFR copy number. Here, we show that mutations activating the RAS/RAF signaling pathway are also predictive and prognostic indicators in mCRC patients, being inversely correlated with response to anti-EGFR mAbs. In cellular models of CRCs, activation of the RAS signaling pathway by introduction of an activated K-RAS allele (Gly 12Val) impairs the therapeutic effect of anti-EGFR mAbs. In cancer cells carrying constitutively active RAS, the pharmacologic inhibition of the mitogen-activated protein kinase (MAPK) signaling cascade improves anti-EGFR treatment based on mAbs. These results have implications for the identification of patients who are likely to respond to anti-EGFR treatment. They also provide the rationale for combination therapies, targeted simultaneously to the EGFR and RAS/ RAF/MAPK signaling pathways in CRC patients.",
author = "Silvia Benvenuti and Andrea Sartore-Bianchi and {Di Nicolantonio}, Federica and Carlo Zanon and Mauro Moroni and Silvio Veronese and Salvatore Siena and Alberto Bardelli",
year = "2007",
month = "3",
day = "15",
doi = "10.1158/0008-5472.CAN-06-4158",
language = "English",
volume = "67",
pages = "2643--2648",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies

AU - Benvenuti, Silvia

AU - Sartore-Bianchi, Andrea

AU - Di Nicolantonio, Federica

AU - Zanon, Carlo

AU - Moroni, Mauro

AU - Veronese, Silvio

AU - Siena, Salvatore

AU - Bardelli, Alberto

PY - 2007/3/15

Y1 - 2007/3/15

N2 - Monoclonal antibodies (mAbs) against the extracellular domain of the epidermal growth factor receptor (EGFR) have been introduced for the treatment of metastatic colorectal cancer (mCRC). We have reported recently that increased copy number of the EGFR can predict response to anti-EGFR mAbs and that patients might be selected for treatment based on EGFR copy number. Here, we show that mutations activating the RAS/RAF signaling pathway are also predictive and prognostic indicators in mCRC patients, being inversely correlated with response to anti-EGFR mAbs. In cellular models of CRCs, activation of the RAS signaling pathway by introduction of an activated K-RAS allele (Gly 12Val) impairs the therapeutic effect of anti-EGFR mAbs. In cancer cells carrying constitutively active RAS, the pharmacologic inhibition of the mitogen-activated protein kinase (MAPK) signaling cascade improves anti-EGFR treatment based on mAbs. These results have implications for the identification of patients who are likely to respond to anti-EGFR treatment. They also provide the rationale for combination therapies, targeted simultaneously to the EGFR and RAS/ RAF/MAPK signaling pathways in CRC patients.

AB - Monoclonal antibodies (mAbs) against the extracellular domain of the epidermal growth factor receptor (EGFR) have been introduced for the treatment of metastatic colorectal cancer (mCRC). We have reported recently that increased copy number of the EGFR can predict response to anti-EGFR mAbs and that patients might be selected for treatment based on EGFR copy number. Here, we show that mutations activating the RAS/RAF signaling pathway are also predictive and prognostic indicators in mCRC patients, being inversely correlated with response to anti-EGFR mAbs. In cellular models of CRCs, activation of the RAS signaling pathway by introduction of an activated K-RAS allele (Gly 12Val) impairs the therapeutic effect of anti-EGFR mAbs. In cancer cells carrying constitutively active RAS, the pharmacologic inhibition of the mitogen-activated protein kinase (MAPK) signaling cascade improves anti-EGFR treatment based on mAbs. These results have implications for the identification of patients who are likely to respond to anti-EGFR treatment. They also provide the rationale for combination therapies, targeted simultaneously to the EGFR and RAS/ RAF/MAPK signaling pathways in CRC patients.

UR - http://www.scopus.com/inward/record.url?scp=34047248571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047248571&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-4158

DO - 10.1158/0008-5472.CAN-06-4158

M3 - Article

VL - 67

SP - 2643

EP - 2648

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 6

ER -